EA202091340A1 - Способ получения соединений "лекарственное средство-линкер" - Google Patents
Способ получения соединений "лекарственное средство-линкер"Info
- Publication number
- EA202091340A1 EA202091340A1 EA202091340A EA202091340A EA202091340A1 EA 202091340 A1 EA202091340 A1 EA 202091340A1 EA 202091340 A EA202091340 A EA 202091340A EA 202091340 A EA202091340 A EA 202091340A EA 202091340 A1 EA202091340 A1 EA 202091340A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- linker compounds
- drug
- producing drug
- compounds
- linker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593104P | 2017-11-30 | 2017-11-30 | |
| PCT/US2018/063070 WO2019108797A1 (en) | 2017-11-30 | 2018-11-29 | Process for the preparation of drug linker compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091340A1 true EA202091340A1 (ru) | 2020-10-16 |
Family
ID=66665808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091340A EA202091340A1 (ru) | 2017-11-30 | 2018-11-29 | Способ получения соединений "лекарственное средство-линкер" |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11612666B2 (https=) |
| EP (1) | EP3717016A4 (https=) |
| JP (2) | JP7402159B2 (https=) |
| KR (2) | KR20250024092A (https=) |
| CN (2) | CN111417408B (https=) |
| AU (1) | AU2018375412B2 (https=) |
| BR (1) | BR112020010503A2 (https=) |
| CA (1) | CA3082165A1 (https=) |
| EA (1) | EA202091340A1 (https=) |
| IL (1) | IL274757B2 (https=) |
| MA (1) | MA51870A (https=) |
| MX (2) | MX2020005565A (https=) |
| SG (1) | SG11202004698RA (https=) |
| WO (1) | WO2019108797A1 (https=) |
| ZA (1) | ZA202003037B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7167163B2 (ja) * | 2019-05-20 | 2022-11-08 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 抗体－薬物コンジュゲートの中間体のワンポット合成法による製造プロセス |
| CN110945009B (zh) * | 2019-10-23 | 2023-10-31 | 烟台迈百瑞国际生物医药股份有限公司 | 一种寡肽连接子中间体及其制备方法 |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN115873066A (zh) * | 2022-07-27 | 2023-03-31 | 吉林省博大伟业制药有限公司 | 一种抗体偶联药物连接子的合成方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US7498298B2 (en) * | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2007031734A1 (en) * | 2005-09-14 | 2007-03-22 | Ucb Pharma S.A. | Comb polymers |
| MX2009002855A (es) * | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales. |
| ES2569483T3 (es) * | 2007-06-21 | 2016-05-11 | Amgen Inc. | Métodos para sintetizar cinacalcet y sales del mismo |
| KR102356286B1 (ko) * | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US9981046B2 (en) * | 2012-05-15 | 2018-05-29 | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. | Drug-conjugates, conjugation methods, and uses thereof |
| SI2941432T1 (en) * | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| GB201416960D0 (en) * | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
| US9533483B2 (en) | 2014-09-26 | 2017-01-03 | Kimberly-Clark Worldwide, Inc. | Apparatus for and method of shaping and applying a segment to a moving web |
-
2018
- 2018-11-29 CN CN201880077478.0A patent/CN111417408B/zh active Active
- 2018-11-29 MA MA051870A patent/MA51870A/fr unknown
- 2018-11-29 BR BR112020010503-1A patent/BR112020010503A2/pt active Search and Examination
- 2018-11-29 MX MX2020005565A patent/MX2020005565A/es unknown
- 2018-11-29 AU AU2018375412A patent/AU2018375412B2/en active Active
- 2018-11-29 KR KR1020257002801A patent/KR20250024092A/ko active Pending
- 2018-11-29 JP JP2020529321A patent/JP7402159B2/ja active Active
- 2018-11-29 SG SG11202004698RA patent/SG11202004698RA/en unknown
- 2018-11-29 CN CN202410349991.8A patent/CN118271394A/zh active Pending
- 2018-11-29 EA EA202091340A patent/EA202091340A1/ru unknown
- 2018-11-29 WO PCT/US2018/063070 patent/WO2019108797A1/en not_active Ceased
- 2018-11-29 KR KR1020207018586A patent/KR102762352B1/ko active Active
- 2018-11-29 US US16/768,027 patent/US11612666B2/en active Active
- 2018-11-29 IL IL274757A patent/IL274757B2/en unknown
- 2018-11-29 CA CA3082165A patent/CA3082165A1/en active Pending
- 2018-11-29 EP EP18883925.2A patent/EP3717016A4/en active Pending
-
2020
- 2020-05-22 ZA ZA2020/03037A patent/ZA202003037B/en unknown
- 2020-07-13 MX MX2023009372A patent/MX2023009372A/es unknown
-
2023
- 2023-01-31 US US18/162,432 patent/US20240042052A1/en not_active Abandoned
- 2023-09-20 JP JP2023152281A patent/JP7787859B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102762352B1 (ko) | 2025-02-05 |
| CN111417408B (zh) | 2024-04-23 |
| BR112020010503A2 (pt) | 2020-10-20 |
| US20200360532A1 (en) | 2020-11-19 |
| MX2020005565A (es) | 2020-08-20 |
| KR20250024092A (ko) | 2025-02-18 |
| CN118271394A (zh) | 2024-07-02 |
| JP2023164652A (ja) | 2023-11-10 |
| SG11202004698RA (en) | 2020-06-29 |
| KR20200094185A (ko) | 2020-08-06 |
| JP7787859B2 (ja) | 2025-12-17 |
| MX2023009372A (es) | 2023-08-16 |
| WO2019108797A1 (en) | 2019-06-06 |
| EP3717016A4 (en) | 2021-09-01 |
| IL274757B1 (en) | 2025-12-01 |
| IL274757A (en) | 2020-07-30 |
| CA3082165A1 (en) | 2019-06-06 |
| US11612666B2 (en) | 2023-03-28 |
| MA51870A (fr) | 2020-10-07 |
| CN111417408A (zh) | 2020-07-14 |
| JP7402159B2 (ja) | 2023-12-20 |
| EP3717016A1 (en) | 2020-10-07 |
| JP2021505542A (ja) | 2021-02-18 |
| IL274757B2 (en) | 2026-04-01 |
| US20240042052A1 (en) | 2024-02-08 |
| AU2018375412A1 (en) | 2020-05-28 |
| ZA202003037B (en) | 2023-12-20 |
| AU2018375412B2 (en) | 2025-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551065A1 (en) | Fused ring compounds | |
| EA202193338A1 (ru) | Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина | |
| CR20210083A (es) | Compuestos de anillo fusionado | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| EA202091340A1 (ru) | Способ получения соединений "лекарственное средство-линкер" | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| NZ702752A (en) | Methods for synthesizing amatoxin building block and amatoxins | |
| MX2021004582A (es) | Compuesto 2-azabiciclo hexano inhibidor de jak. | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| SG11201906688VA (en) | Novel ester compounds, method for the production thereof and use thereof | |
| MX2018004923A (es) | Aceite de sabadilla. | |
| EA202090414A1 (ru) | Соединения и их применение | |
| EA201891770A1 (ru) | Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| EA201990998A1 (ru) | Фармацевтические составы и способы их получения | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| SA522431585B1 (ar) | تركيبات تروفينتايد | |
| CR20220231A (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| EA202190330A1 (ru) | Способ получения полиморфной формы робенакоксиба | |
| MX2021000226A (es) | Nuevo proceso para la preparacion de diamidas antranilicas. | |
| PH12020500393A1 (en) | Mpges-1 inhibitor for the treatment of osteoarthritis pain |